Jazz Pharmaceuticals PLC $JAZZ Shares Acquired by Bank of Montreal Can

Bank of Montreal Can increased its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 157.7% in the second quarter, Holdings Channel.com reports. The firm owned 328,475 shares of the specialty pharmaceutical company’s stock after purchasing an additional 201,008 shares during the period. Bank of Montreal Can’s holdings in Jazz Pharmaceuticals were worth $34,858,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the business. Nuveen LLC purchased a new stake in Jazz Pharmaceuticals in the 1st quarter valued at about $62,362,000. Fuller & Thaler Asset Management Inc. boosted its position in shares of Jazz Pharmaceuticals by 41.7% in the first quarter. Fuller & Thaler Asset Management Inc. now owns 1,331,011 shares of the specialty pharmaceutical company’s stock worth $165,245,000 after acquiring an additional 391,660 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Jazz Pharmaceuticals by 14.4% in the first quarter. Dimensional Fund Advisors LP now owns 2,328,430 shares of the specialty pharmaceutical company’s stock worth $289,066,000 after acquiring an additional 293,360 shares during the last quarter. Allianz Asset Management GmbH grew its holdings in Jazz Pharmaceuticals by 453.9% in the second quarter. Allianz Asset Management GmbH now owns 325,403 shares of the specialty pharmaceutical company’s stock valued at $34,532,000 after purchasing an additional 266,658 shares during the period. Finally, Boston Trust Walden Corp increased its position in Jazz Pharmaceuticals by 129.1% during the second quarter. Boston Trust Walden Corp now owns 407,897 shares of the specialty pharmaceutical company’s stock worth $43,286,000 after purchasing an additional 229,885 shares during the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Bruce C. Cozadd sold 3,500 shares of the business’s stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $140.00, for a total transaction of $490,000.00. Following the transaction, the director directly owned 408,826 shares of the company’s stock, valued at approximately $57,235,640. The trade was a 0.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold a total of 11,500 shares of company stock worth $1,525,280 in the last 90 days. Company insiders own 4.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on JAZZ. Wells Fargo & Company set a $170.00 price target on shares of Jazz Pharmaceuticals in a report on Wednesday, October 22nd. The Goldman Sachs Group boosted their price target on Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a “buy” rating in a research report on Friday, August 29th. JPMorgan Chase & Co. cut their price objective on Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating on the stock in a report on Monday, October 27th. Deutsche Bank Aktiengesellschaft began coverage on Jazz Pharmaceuticals in a research note on Tuesday, July 15th. They issued a “buy” rating and a $152.00 price objective on the stock. Finally, Zacks Research raised shares of Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Friday, August 15th. Thirteen investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $178.50.

Jazz Pharmaceuticals Trading Down 2.3%

Shares of JAZZ opened at $134.05 on Friday. Jazz Pharmaceuticals PLC has a 12 month low of $95.49 and a 12 month high of $148.06. The stock’s 50-day moving average is $133.14 and its two-hundred day moving average is $119.09. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37. The stock has a market cap of $8.13 billion, a PE ratio of -19.92, a P/E/G ratio of 8.49 and a beta of 0.29.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Wednesday, November 5th. The specialty pharmaceutical company reported $8.13 EPS for the quarter, beating the consensus estimate of $5.87 by $2.26. The business had revenue of $1.13 billion for the quarter, compared to the consensus estimate of $1.11 billion. Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The company’s revenue was up 6.7% on a year-over-year basis. During the same period last year, the business posted $6.54 EPS. Jazz Pharmaceuticals has set its FY 2025 guidance at 7.650-8.450 EPS. Equities analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.